Additionally, AMG 673, a novel HLE bispecific antibody that binds CD33 and CD3 with fused single chain IgG Fc, was studied in R/R AML by infusing two doses over 14 days, demonstrating longer half-life than prior bispecific antibody constructs [29]. The gene discussed is CD33; the disease is acute myeloid leukemia.